IDEAS home Printed from https://ideas.repec.org/a/nat/nature/v547y2017i7661d10.1038_nature22964.html
   My bibliography  Save this article

mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer

Author

Listed:
  • Amaia Zabala-Letona

    (CIC bioGUNE, Bizkaia Technology Park
    CIBERONC, Instituto de Salud Carlos III, C/ Monforte de Lemos 3-5)

  • Amaia Arruabarrena-Aristorena

    (CIC bioGUNE, Bizkaia Technology Park)

  • Natalia Martín-Martín

    (CIC bioGUNE, Bizkaia Technology Park
    CIBERONC, Instituto de Salud Carlos III, C/ Monforte de Lemos 3-5)

  • Sonia Fernandez-Ruiz

    (CIC bioGUNE, Bizkaia Technology Park
    CIBERONC, Instituto de Salud Carlos III, C/ Monforte de Lemos 3-5)

  • James D. Sutherland

    (CIC bioGUNE, Bizkaia Technology Park)

  • Michelle Clasquin

    (AGIOS Pharmaceuticals)

  • Julen Tomas-Cortazar

    (CIC bioGUNE, Bizkaia Technology Park)

  • Jose Jimenez

    (Vall d’Hebron Institute of Oncology (VHIO), Universidad Autónoma de Barcelona)

  • Ines Torres

    (Valld’Hebron Hospital, Universitat Autónoma de Barcelona)

  • Phong Quang

    (AGIOS Pharmaceuticals)

  • Pilar Ximenez-Embun

    (Spanish National Cancer Research Centre (CNIO))

  • Ruzica Bago

    (MRC Protein Phosphorylation and Ubiquitylation Unit, College of Life Sciences, University of Dundee)

  • Aitziber Ugalde-Olano

    (Basurto University Hospital)

  • Ana Loizaga-Iriarte

    (Basurto University Hospital)

  • Isabel Lacasa-Viscasillas

    (Basurto University Hospital)

  • Miguel Unda

    (Basurto University Hospital)

  • Verónica Torrano

    (CIC bioGUNE, Bizkaia Technology Park
    CIBERONC, Instituto de Salud Carlos III, C/ Monforte de Lemos 3-5)

  • Diana Cabrera

    (CIC bioGUNE, Bizkaia Technology Park)

  • Sebastiaan M. van Liempd

    (CIC bioGUNE, Bizkaia Technology Park)

  • Ylenia Cendon

    (Spanish National Cancer Research Centre (CNIO)
    School of Medicine, Universidad Autónoma de Madrid)

  • Elena Castro

    (Spanish National Cancer Research Centre (CNIO))

  • Stuart Murray

    (AGIOS Pharmaceuticals)

  • Ajinkya Revandkar

    (Institute of Oncology Research (IOR) and Oncology Institute of Southern Switzerland (IOSI)
    Faculty of Biology and Medicine, University of Lausanne (UNIL))

  • Andrea Alimonti

    (Institute of Oncology Research (IOR) and Oncology Institute of Southern Switzerland (IOSI)
    Faculty of Biology and Medicine, University of Lausanne (UNIL))

  • Yinan Zhang

    (Harvard School of Public Health)

  • Amelia Barnett

    (AGIOS Pharmaceuticals)

  • Gina Lein

    (AGIOS Pharmaceuticals)

  • David Pirman

    (AGIOS Pharmaceuticals)

  • Ana R. Cortazar

    (CIC bioGUNE, Bizkaia Technology Park)

  • Leire Arreal

    (CIC bioGUNE, Bizkaia Technology Park)

  • Ludmila Prudkin

    (Vall d’Hebron Institute of Oncology (VHIO), Universidad Autónoma de Barcelona)

  • Ianire Astobiza

    (CIC bioGUNE, Bizkaia Technology Park)

  • Lorea Valcarcel-Jimenez

    (CIC bioGUNE, Bizkaia Technology Park)

  • Patricia Zuñiga-García

    (CIC bioGUNE, Bizkaia Technology Park)

  • Itziar Fernandez-Dominguez

    (CIC bioGUNE, Bizkaia Technology Park)

  • Marco Piva

    (CIC bioGUNE, Bizkaia Technology Park)

  • Alfredo Caro-Maldonado

    (CIC bioGUNE, Bizkaia Technology Park)

  • Pilar Sánchez-Mosquera

    (CIC bioGUNE, Bizkaia Technology Park)

  • Mireia Castillo-Martín

    (Icahn School of Medicine at Mount Sinai
    Fundação Champalimaud)

  • Violeta Serra

    (CIBERONC, Instituto de Salud Carlos III, C/ Monforte de Lemos 3-5
    Vall d’Hebron Institute of Oncology (VHIO), Universidad Autónoma de Barcelona)

  • Naiara Beraza

    (CIC bioGUNE, Bizkaia Technology Park
    Institute of Food Research, Norwich Research Park)

  • Antonio Gentilella

    (Laboratory of Metabolism and Cancer, Catalan Institute of Oncology, ICO, Bellvitge Biomedical Research Institute
    Faculty of Pharmacy, Universitat de Barcelona)

  • George Thomas

    (Laboratory of Metabolism and Cancer, Catalan Institute of Oncology, ICO, Bellvitge Biomedical Research Institute)

  • Mikel Azkargorta

    (CIC bioGUNE, Bizkaia Technology Park
    Carlos III Networked Proteomics Platform (ProteoRed-ISCIII), Instituto de Salud Carlos III, C/ Monforte de Lemos 3-5)

  • Felix Elortza

    (CIC bioGUNE, Bizkaia Technology Park
    Carlos III Networked Proteomics Platform (ProteoRed-ISCIII), Instituto de Salud Carlos III, C/ Monforte de Lemos 3-5
    Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, C/ Monforte de Lemos 3-5)

  • Rosa Farràs

    (Centro de Investigación Príncipe Felipe)

  • David Olmos

    (Spanish National Cancer Research Centre (CNIO)
    CNIO-IBIMA Genitourinary Cancer Unit, Hospitales Universitarios Virgen de la Victoria y Regional de Málaga)

  • Alejo Efeyan

    (Spanish National Cancer Research Centre (CNIO))

  • Juan Anguita

    (CIC bioGUNE, Bizkaia Technology Park
    Ikerbasque, Basque foundation for science)

  • Javier Muñoz

    (Spanish National Cancer Research Centre (CNIO)
    Carlos III Networked Proteomics Platform (ProteoRed-ISCIII), Instituto de Salud Carlos III, C/ Monforte de Lemos 3-5)

  • Juan M. Falcón-Pérez

    (CIC bioGUNE, Bizkaia Technology Park
    Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, C/ Monforte de Lemos 3-5
    Ikerbasque, Basque foundation for science)

  • Rosa Barrio

    (CIC bioGUNE, Bizkaia Technology Park)

  • Teresa Macarulla

    (CIBERONC, Instituto de Salud Carlos III, C/ Monforte de Lemos 3-5
    Vall d’Hebron Institute of Oncology (VHIO), Universidad Autónoma de Barcelona)

  • Jose M. Mato

    (CIC bioGUNE, Bizkaia Technology Park
    Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, C/ Monforte de Lemos 3-5)

  • Maria L. Martinez-Chantar

    (CIC bioGUNE, Bizkaia Technology Park
    Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, C/ Monforte de Lemos 3-5)

  • Carlos Cordon-Cardo

    (Icahn School of Medicine at Mount Sinai)

  • Ana M. Aransay

    (CIC bioGUNE, Bizkaia Technology Park
    Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, C/ Monforte de Lemos 3-5)

  • Kevin Marks

    (AGIOS Pharmaceuticals)

  • José Baselga

    (Human Oncology & Pathogenesis Program, Memorial Sloan-Kettering Cancer Center)

  • Josep Tabernero

    (CIBERONC, Instituto de Salud Carlos III, C/ Monforte de Lemos 3-5
    Vall d’Hebron Institute of Oncology (VHIO), Universidad Autónoma de Barcelona)

  • Paolo Nuciforo

    (Vall d’Hebron Institute of Oncology (VHIO), Universidad Autónoma de Barcelona)

  • Brendan D. Manning

    (Harvard School of Public Health)

  • Katya Marjon

    (AGIOS Pharmaceuticals)

  • Arkaitz Carracedo

    (CIC bioGUNE, Bizkaia Technology Park
    CIBERONC, Instituto de Salud Carlos III, C/ Monforte de Lemos 3-5
    Ikerbasque, Basque foundation for science
    University of the Basque Country (UPV/EHU))

Abstract

mTOR complex 1 signalling regulates polyamine metabolism and thereby promotes tumorigenesis, through regulation of the stability of a key enzyme, AMD1.

Suggested Citation

  • Amaia Zabala-Letona & Amaia Arruabarrena-Aristorena & Natalia Martín-Martín & Sonia Fernandez-Ruiz & James D. Sutherland & Michelle Clasquin & Julen Tomas-Cortazar & Jose Jimenez & Ines Torres & Phong, 2017. "mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer," Nature, Nature, vol. 547(7661), pages 109-113, July.
    • Handle: RePEc:nat:nature:v:547:y:2017:i:7661:d:10.1038_nature22964
    DOI: 10.1038/nature22964
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/nature22964
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1038/nature22964?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:547:y:2017:i:7661:d:10.1038_nature22964. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.